ESR1 and breast carcinoma: The TEAL study only enrolled 30 evaluable patients, which reported that the combination of T-DM1, lapatinib, and nab-paclitaxel was more effective than trastuzumab, pertuzumab, and paclitaxel as neoadjuvant therapy in HER2-positive breast cancer, especially for estrogen receptor-positive patients [34].